-
1.Compounds useful for the treatment of conditions associated with weight gain 失效
标题翻译: 可用于治疗与体重增加相关的病症的化合物公开(公告)号:US08093248B2
公开(公告)日:2012-01-10
申请号:US12315831
申请日:2008-12-05
申请人: Joseph W. Boyd , Giles A. Brown , Michael Higginbottom , Viet-Anh Anne Horgan (Nee Nguyen) , Jaqueline Ouzman , Iain Simpson
发明人: Joseph W. Boyd , Giles A. Brown , Michael Higginbottom , Viet-Anh Anne Horgan (Nee Nguyen) , Jaqueline Ouzman , Iain Simpson
IPC分类号: C07D295/185 , C07D401/12 , A61K31/496
CPC分类号: C07D295/205
摘要: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.
摘要翻译: 本申请涉及新的式(I)化合物,包含该化合物的药物组合物,其制备方法,以及该化合物作为瘦蛋白受体调节剂模拟物在制备抗体与增重相关的病症中的用途, 2型糖尿病和血脂异常。
-
公开(公告)号:US20090281087A1
公开(公告)日:2009-11-12
申请号:US12315831
申请日:2008-12-05
申请人: Joseph W. Boyd , Giles A. Brown , Michael Higginbottom , Viet-Anh Anne Horgan (nee Nguyen) , Jaqueline Ouzman , Iain Simpson
发明人: Joseph W. Boyd , Giles A. Brown , Michael Higginbottom , Viet-Anh Anne Horgan (nee Nguyen) , Jaqueline Ouzman , Iain Simpson
IPC分类号: A61K31/551 , C07D401/02 , A61K31/496 , C07D403/02 , C07D241/04 , C07D243/08 , A61P3/04 , A61P3/00 , A61P15/08 , A61P37/00 , A61P29/00 , A61P9/00
CPC分类号: C07D295/205
摘要: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.
摘要翻译: 本申请涉及新的式(I)化合物,包含该化合物的药物组合物,其制备方法,以及该化合物作为瘦蛋白受体调节剂模拟物在制备抗体与增重相关的病症中的用途, 2型糖尿病和血脂异常。
-
3.
公开(公告)号:US20110275637A1
公开(公告)日:2011-11-10
申请号:US12996614
申请日:2009-06-04
申请人: Emma Chapman , Michael Higginbottom , Viet-Anh Anne Horgan (nee Nguyen) , James Horton , Iain Simpson , Charles Tyzack
发明人: Emma Chapman , Michael Higginbottom , Viet-Anh Anne Horgan (nee Nguyen) , James Horton , Iain Simpson , Charles Tyzack
IPC分类号: A61K31/5377 , C07D401/12 , A61K31/4439 , A61K31/496 , A61K31/4545 , A61P3/04 , A61P3/10 , A61P5/50 , A61P3/00 , A61P3/06 , A61P1/16 , A61P5/02 , A61P9/12 , A61P7/00 , A61P15/08 , A61P17/00 , A61P15/00 , A61P37/04 , A61P29/00 , A61P9/10 , C07D413/12
CPC分类号: C07D213/30 , C07D213/40 , C07D401/12 , C07D413/12
摘要: The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.
摘要翻译: 本发明涉及新的式(I)化合物,包含这些化合物的药物组合物以及这些化合物作为瘦素受体调节剂模拟物在制备与增重,2型糖尿病和血脂异常相关的病症的药物中的用途。
-
公开(公告)号:US20090203695A1
公开(公告)日:2009-08-13
申请号:US12315830
申请日:2008-12-05
IPC分类号: A61K31/5377 , C07D413/02 , A61P3/04 , A61P3/10 , A61P15/08 , A61P37/00 , A61P17/02 , A61P29/00 , A61P9/00
CPC分类号: C07D211/34 , C07D295/205
摘要: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.
摘要翻译: 本申请涉及新的式(I)化合物,包含该化合物的药物组合物,其制备方法,以及该化合物作为瘦蛋白受体调节剂模拟物在制备抗体与增重相关的病症中的用途, 2型糖尿病和血脂异常。
-
公开(公告)号:US09150574B2
公开(公告)日:2015-10-06
申请号:US14344417
申请日:2011-09-14
申请人: David Evans , Allison Carley , Alison Stewart , Michael Higginbottom , Edward Savory , Iain Simpson , Marianne Nilsson , Martin Haraldsson , Erik Nordling , Tobias Koolmeister
发明人: David Evans , Allison Carley , Alison Stewart , Michael Higginbottom , Edward Savory , Iain Simpson , Marianne Nilsson , Martin Haraldsson , Erik Nordling , Tobias Koolmeister
IPC分类号: C07D471/02 , A61K31/55 , C07D471/04
CPC分类号: C07D471/04
摘要: 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; ethyl 1-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide; 4-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4yl}carbonyl)morpholine; 1-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)piperazine; {4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}methanol; {4-[1-(4-methyl-phenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methanol; [(3R)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol; methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxylate; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxamide; 2-{4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}ethan-1-ol; methyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxylate; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxamide; 1-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine; 1-(4-chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-4-ol; N-butyl-1-(4-chlorophenyl)-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine; 1-[4-(fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine; and 3-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}methyl)pyridine are useful for the inhibition of SSAO activity.
-
公开(公告)号:US20130324556A1
公开(公告)日:2013-12-05
申请号:US13981960
申请日:2012-01-27
申请人: Joe William Boyd , Paul Meo , Michael Higginbottom , Iain Simpson , David Mark Mountford , Edward Daniel Savory
发明人: Joe William Boyd , Paul Meo , Michael Higginbottom , Iain Simpson , David Mark Mountford , Edward Daniel Savory
IPC分类号: C07D211/16 , C07D211/18 , C07D401/06 , C07D211/46 , C07D471/04 , C07D211/54 , C07D211/62 , C07D295/215 , C07D207/06 , C07D413/04 , C07D211/22 , C07D211/58
CPC分类号: C07D211/16 , C07D207/06 , C07D211/18 , C07D211/20 , C07D211/22 , C07D211/46 , C07D211/54 , C07D211/58 , C07D211/62 , C07D295/185 , C07D295/192 , C07D295/215 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D413/04 , C07D471/04
摘要: A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrate thereof Wherein Y, Z, R3, U, R4, m and n are as defined in the claims.
摘要翻译: 式(I)化合物或其药学上可接受的盐,溶剂化物或水合物。其中Y,Z,R3,U,R4,m和n如权利要求中所定义。
-
7.7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS 审中-公开
标题翻译: 7-羟基 - 吡唑并[1,5-A]吡嗪化合物及其作为CCR2受体拮抗剂的用途公开(公告)号:US20130252951A1
公开(公告)日:2013-09-26
申请号:US13876220
申请日:2011-09-26
申请人: Joe William Boyd , Paul Meo , Michael Higginbottom , Iain Simpson , David Mountford , Edward Daniel Savory
发明人: Joe William Boyd , Paul Meo , Michael Higginbottom , Iain Simpson , David Mountford , Edward Daniel Savory
IPC分类号: C07D487/04
CPC分类号: C07D487/04
摘要: The compounds of formula (I) are antagonists of the CCR2 receptor Wherein R1-7 and A are as defined in the claims.
摘要翻译: 式(I)化合物是CCR2受体的拮抗剂,其中R1-7和A如权利要求中所定义。
-
公开(公告)号:US20130102587A1
公开(公告)日:2013-04-25
申请号:US13634732
申请日:2011-03-14
申请人: David Evans , Allison Carley , Alison Stewart , Michael Higginbottom , Edward Savory , Iain Simpson , Marianne Nilsson , Martin Haraldsson , Erik Nordling , Tobias Koolmeister
发明人: David Evans , Allison Carley , Alison Stewart , Michael Higginbottom , Edward Savory , Iain Simpson , Marianne Nilsson , Martin Haraldsson , Erik Nordling , Tobias Koolmeister
IPC分类号: C07D471/04 , C07D491/08 , C07D487/04
CPC分类号: C07D471/04 , C07D487/04 , C07D491/08 , C07D498/08 , C07D519/00
摘要: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.
摘要翻译: 公开了抑制SSAO酶活性的化合物。 还公开了包含这些化合物的药物组合物以及这些化合物在治疗或预防其中抑制SSAO活性有益的医学病症中的用途,例如炎性疾病,免疫疾病和抑制肿瘤生长。
-
9.
公开(公告)号:US20110275678A1
公开(公告)日:2011-11-10
申请号:US12996619
申请日:2009-06-04
申请人: Michael Higginbottom , Anne Viet-Anh Horgan (nee Nguyen) , James Horton , Iain Simpson , Charles Tyzack
发明人: Michael Higginbottom , Anne Viet-Anh Horgan (nee Nguyen) , James Horton , Iain Simpson , Charles Tyzack
IPC分类号: A61K31/4439 , C07D405/12 , C07D413/12 , A61K31/4409 , A61K31/443 , A61P3/10 , A61P3/06 , A61P5/48 , A61P3/00 , A61P1/16 , A61P5/02 , A61P9/12 , A61P7/00 , A61P15/08 , A61P17/00 , A61P25/00 , A61P15/00 , A61P37/00 , A61P29/00 , A61P9/10 , A61P3/04 , C07D213/55
CPC分类号: C07D213/30 , C07D405/12 , C07D413/12
摘要: The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.
摘要翻译: 本发明涉及新的式(I)化合物,包含这些化合物的药物组合物以及这些化合物作为瘦素受体调节剂模拟物在制备与增重,2型糖尿病和血脂异常相关的病症的药物中的用途。
-
公开(公告)号:US09227967B2
公开(公告)日:2016-01-05
申请号:US13634732
申请日:2011-03-14
申请人: David Evans , Allison Carley , Alison Stewart , Michael Higginbottom , Edward Savory , Iain Simpson , Marianne Nilsson , Martin Haraldsson , Erik Nordling , Tobias Koolmeister
发明人: David Evans , Allison Carley , Alison Stewart , Michael Higginbottom , Edward Savory , Iain Simpson , Marianne Nilsson , Martin Haraldsson , Erik Nordling , Tobias Koolmeister
IPC分类号: C07D471/04 , C07D487/04 , C07D498/08 , C07D519/00 , C07D491/08
CPC分类号: C07D471/04 , C07D487/04 , C07D491/08 , C07D498/08 , C07D519/00
摘要: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
摘要翻译: 公开了抑制SSAO酶活性的化合物。 还公开了包含这些化合物的药物组合物以及这些化合物在治疗或预防其中抑制SSAO活性有益的医学病症中的用途,例如炎性疾病,免疫疾病和抑制肿瘤生长。
-
-
-
-
-
-
-
-
-